40P Efficacy and safety of immune checkpoint inhibitors in previously treated metastatic non-small cell lung cancer

40P Efficacy and safety of immune checkpoint inhibitors in previously treated metastatic non-small cell lung cancer is a paper indexed in ScholarIQ from OpenAlex.

How many citations does 40P Efficacy and safety of immune checkpoint inhibitors in previously treated metastatic non-small cell lung cancer have?

40P Efficacy and safety of immune checkpoint inhibitors in previously treated metastatic non-small cell lung cancer has 0 citations in the OpenAlex counts ScholarIQ stores.

When was 40P Efficacy and safety of immune checkpoint inhibitors in previously treated metastatic non-small cell lung cancer published?

40P Efficacy and safety of immune checkpoint inhibitors in previously treated metastatic non-small cell lung cancer has 2020 year in the ScholarIQ index.

What is the open-access status of 40P Efficacy and safety of immune checkpoint inhibitors in previously treated metastatic non-small cell lung cancer?

40P Efficacy and safety of immune checkpoint inhibitors in previously treated metastatic non-small cell lung cancer has closed oa status in the ScholarIQ index.

What is the DOI of 40P Efficacy and safety of immune checkpoint inhibitors in previously treated metastatic non-small cell lung cancer?

The DOI for 40P Efficacy and safety of immune checkpoint inhibitors in previously treated metastatic non-small cell lung cancer is on the source record.

What is the OpenAlex record for 40P Efficacy and safety of immune checkpoint inhibitors in previously treated metastatic non-small cell lung cancer?

The OpenAlex for 40P Efficacy and safety of immune checkpoint inhibitors in previously treated metastatic non-small cell lung cancer is on the source record.